204 related articles for article (PubMed ID: 28142395)
1. Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
Dentone C; Sterrantino G; Signori A; Cenderello G; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Giacomini M; Bruzzone B; Francisci D; Di Biagio A;
Int J STD AIDS; 2017 Oct; 28(11):1067-1073. PubMed ID: 28142395
[TBL] [Abstract][Full Text] [Related]
2. Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
Potard V; Reynes J; Ferry T; Aubin C; Finkielsztejn L; Yazdanpanah Y; Costagliola D;
PLoS One; 2015; 10(12):e0144746. PubMed ID: 26714012
[TBL] [Abstract][Full Text] [Related]
3. Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.
Ruiz-Mateos E; González-Serna A; Genebat M; Machmach K; Vidal F; Muñoz-Fernández A; Ferrando-Martinez S; Leal M
Antimicrob Agents Chemother; 2011 Oct; 55(10):4664-9. PubMed ID: 21807977
[TBL] [Abstract][Full Text] [Related]
4. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
[TBL] [Abstract][Full Text] [Related]
6. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
7. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
[TBL] [Abstract][Full Text] [Related]
8. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
Minami R; Takahama S; Kaku Y; Yamamoto M
J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
Blanco JR; Arroyo-Manzano D; Rojas-Liévano JF; Crespo M; Bravo I; Pasquau J; Garcia Del Toro M; Herrero C; Rivero A; Moreno S; Llibre JM
AIDS Res Hum Retroviruses; 2015 Sep; 31(9):893-7. PubMed ID: 26059859
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
12. Effect of maraviroc on HIV disease progression-related biomarkers.
Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
Bocket L; Peytavin G; Alidjinou EK; Ajana F; Choisy P; Lê M; Charpentier C; Descamps D; Yazdanpanah Y; Katlama C; Simon A; Calvez V; Marcelin AG; Soulie C
J Antimicrob Chemother; 2016 Sep; 71(9):2651-3. PubMed ID: 27234463
[TBL] [Abstract][Full Text] [Related]
14. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
15. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
16. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
[TBL] [Abstract][Full Text] [Related]
18. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
Wilkin TJ; Lalama CM; McKinnon J; Gandhi RT; Lin N; Landay A; Ribaudo H; Fox L; Currier JS; Mellors JW; Gulick R; Tenorio AR
J Infect Dis; 2012 Aug; 206(4):534-42. PubMed ID: 22740718
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Tiraboschi JM; Niubo J; Curto J; Podzamczer D
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):606-9. PubMed ID: 20706127
[TBL] [Abstract][Full Text] [Related]
20. The maraviroc expanded access program - safety and efficacy data from an open-label study.
Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
